Plain-English translation of NCT06483100 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study evaluates a personalized approach to treating newly diagnosed multiple myeloma after stem cell transplant. Patients receive elranatamab as maintenance treatment, but how long they take it depends on special blood tests that look for remaining myeloma cells. The goal is to use these tests to guide treatment decisions—continuing the medication when needed and stopping it when the disease is well-controlled.
Some myeloma patients still have residual disease (lingering cancer cells) even after transplant and initial treatment, which increases the risk of relapse. This trial explores whether personalizing maintenance therapy based on blood test results can improve long-term outcomes while avoiding unnecessary treatment.
You likely qualify if…
You likely don't qualify if…
You will receive at least 12 months of maintenance medication infusions as an outpatient. Every 6 months, you will have a bone marrow blood test to check for remaining myeloma cells. If two consecutive tests show no detectable disease, your medication will be stopped and you will move to an observation phase with less frequent visits (every 3 months for routine checks, bone marrow tests every 6 months). If myeloma cells reappear, you restart the medication. The entire study can last up to 3 years, and you will be monitored closely throughout.
AI-generated summary from trial data · Aug 18, 2026 · Not medical advice
United States